Profile: Allakos Inc (ALLK.OQ)
Allakos, Inc. incorporated on March 9, 2012, is a clinical-stage biotechnology company. The Company is focused on providing treatments by developing monoclonal antibodies that selectively target mast cells and eosinophils related diseases. The Company's antibodies target receptor molecules present on the surface of immune effector cells, which are involved in allergy, inflammation and tissue damage.
The Company is testing AK002 in a double-blind, placebo-controlled Phase 2 trial in patients, which is an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. The Company's AK002 is used in the treatment of various diseases with abnormal proliferation of mast cells, including eosinophilic gastritis (EG), indolent systemic mastocytosis, urticaria and allergic conjunctivitis.
975 Island Dr Ste 201
REDWOOD CITY CA 94065-5173